Market Place
Sourcing Support
Enlivex Lists RAIN Token on Leading HTX Exchange
30 Apr 2026 //
GLOBENEWSWIRE
Enlivex Boosts RAIN Holdings To 78.8B Tokens, Worth $567M
28 Apr 2026 //
GLOBENEWSWIRE
Enlivex Reports Full-Year 2025 Results
25 Mar 2026 //
GLOBENEWSWIRE
Enlivex Announces $21 M Debt Financing, $20M Share Repurchase
24 Mar 2026 //
GLOBENEWSWIRE
Enlivex Updates Treasury: RAIN Token Listed On Kraken Exchange
10 Feb 2026 //
GLOBENEWSWIRE
Enlivex Updates Treasury: RAIN Token Listed On Whitebit Exchange
26 Jan 2026 //
GLOBENEWSWIRE
Enlivex Lists RAIN Token On Kucoin Cryptocurrency Exchange
07 Jan 2026 //
GLOBENEWSWIRE
Enlivex To Host Fireside Chat On RAIN Token Strategy
04 Dec 2025 //
GLOBENEWSWIRE
Enlivex Finalizes $212M Private Placement
26 Nov 2025 //
GLOBENEWSWIRE
Boral Capital Hosts Kol Webinar On Enlivex`s Knee Osteoarthritis
29 Sep 2025 //
GLOBENEWSWIRE
Enlivex Wins Patent for Allocetra Use in Osteoarthritis Therapy
09 Sep 2025 //
GLOBENEWSWIRE
Enlivex Reports Positive Results from Knee Osteoarthritis Trial
18 Aug 2025 //
GLOBENEWSWIRE
Enlivex Sets August 18, 2025 For Ph II Topline Data Announcement
28 Jul 2025 //
GLOBENEWSWIRE
Enlivex to Present Allocetra Data at EULAR 25 Congress
10 Jun 2025 //
GLOBENEWSWIRE
Enlivex Selected to Present at Israeli BioMed 2025 Conference
20 May 2025 //
GLOBENEWSWIRE
Enlivex Therapeutics to Present Allocetra at OARSI 2025 Congress
23 Apr 2025 //
GLOBENEWSWIRE
Enlivex doses first patient in Phase I trial for TMJ Osteoarthritis
03 Apr 2025 //
GLOBENEWSWIRE
Enlivex: 47% Pain Reduction In Knee OA At Six Months
03 Mar 2025 //
GLOBENEWSWIRE
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
18 Feb 2025 //
GLOBENEWSWIRE
Enlivex Adopts Bitcoin Treasury Reserve Strategy
20 Nov 2024 //
GLOBENEWSWIRE
Enlivex Receives Authorization For Phase II Trial Of Allocetra
26 Sep 2024 //
GLOBENEWSWIRE
Enlivex Gets Positive DSMB for Phase II Allocetra Trial
24 Sep 2024 //
GLOBENEWSWIRE
Enlivex Authorized To Start Phase I Trial Of Allocetra In Psoriatic Arthritis
23 Jul 2024 //
GLOBENEWSWIRE
Enlivex Therapeutics CEO To Host Live Investor Webinar And Q&A On June 25
20 Jun 2024 //
GLOBENEWSWIRE
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
29 May 2024 //
GLOBENEWSWIRE
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
28 May 2024 //
GLOBENEWSWIRE
Enlivex lays off 50% of staff; Moderna warns against TRC Capital
11 Sep 2023 //
ENDPTS
Enlivex Announces Reprioritization Plan & Second Quarter 2023 Financial Results
11 Sep 2023 //
GLOBENEWSWIRE
Enlivex to Present at H.C. Wainwright 25th Annual Global Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Enlivex Announces Q1 2023 Financial Results and Provides a Business Update
26 Jun 2023 //
GLOBENEWSWIRE
Enlivex to Present at the 2023 Jefferies Healthcare Conference
06 Jun 2023 //
GLOBENEWSWIRE
Enlivex Selected for an Elevator Pitch Presentation
31 May 2023 //
GLOBENEWSWIRE
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering
19 Apr 2023 //
GLOBENEWSWIRE
Enlivex Appoints Andrew Singer to its Board of Directors
17 Apr 2023 //
GLOBENEWSWIRE
Enlivex Receives Positive DSMB Recommendation to Continue P I/II
20 Mar 2023 //
GLOBENEWSWIRE
Enlivex Receives Clearance For Advanced Solid Malignancies in PI/II Trial
23 Feb 2023 //
GLOBENEWSWIRE
Enlivex Announces DSMB Recommendation to Continue PI/II Trial of Allocetra
25 Jan 2023 //
GLOBENEWSWIRE
Enlivex Receives Authorizations from Agencies To Expand PII Sepsis Trial
04 Jan 2023 //
GLOBENEWSWIRE
Enlivex Receives Allocetra IND Clearance From The U.S. FDA
28 Nov 2022 //
GLOBENEWSWIRE
Enlivex Announces Dosing of First Patient in PI/II Trial Evaluating Allocetra
15 Nov 2022 //
GLOBENEWSWIRE
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
03 Oct 2022 //
GLOBENEWSWIRE
Enlivex to Present at Upcoming Investor and Media Conferences
13 Sep 2022 //
GLOBENEWSWIRE
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing
12 Sep 2022 //
GLOBENEWSWIRE
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering
29 Aug 2022 //
GLOBENEWSWIRE
Enlivex Announces Regulatory Clearance for Frozen Allocetra Formulation
24 Aug 2022 //
GLOBENEWSWIRE
Enlivex Announces Second Quarter 2022 Financial Results
22 Aug 2022 //
GLOBENEWSWIRE
Enlivex receives approval for Phase I/II solid tumour trial in Israel
18 Aug 2022 //
CLINICALTRIALSARENA
Enlivex Receives Approval for the PI/II Trial Evaluating Allocetra
17 Aug 2022 //
GLOBENEWSWIRE
Enlivex Receives Notice of Allowance for U.S. Patent Application of Allocetra
03 Aug 2022 //
GLOBENEWSWIRE
Sheba, Enlivex Begins Dosing in PI/II Trial of Allocetra + Chemotherapy
06 Jul 2022 //
GLOBENEWSWIRE
Enlivex to Present at the 2022 Jefferies Healthcare Conference
07 Jun 2022 //
GLOBENEWSWIRE
Enlivex Receives Israeli MHA for Initiation of PI/II Trial of Allocetra
06 Jun 2022 //
GLOBENEWSWIRE
Enlivex Announces New Preclinical Data in Ovarian Cancer on Survival Benefit
31 May 2022 //
GLOBENEWSWIRE
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant
25 May 2022 //
PRESS RELEASE
Enlivex Appoints Dr. Roger J. Pomerantz to Board of Directors as Vice Chairman
23 May 2022 //
GLOBENEWSWIRE
Enlivex to Present at the H.C. Wainwright Global Investment Conference
19 May 2022 //
GLOBENEWSWIRE
Enlivex Announces Upcoming May Conference Presentations
10 May 2022 //
GLOBENEWSWIRE
Enlivex Presented Survival Benefit of Allocetra + Immune Checkpoint Inhibitor
09 May 2022 //
GLOBENEWSWIRE
Enlivex Bags 2 U.S. Patents Covering Methods of Treating Sepsis with Allocetra
05 May 2022 //
GLOBENEWSWIRE
Enlivex Announces Full Year 2021 Financial Results
29 Apr 2022 //
GLOBENEWSWIRE
